IONS

43.09

0.19% +0.08

시간 외 거래: 43.09

Ionis Pharmaceuticals Inc (IONS)

개요 뉴스 가격 이력 옵션 체인 Financials 토론 예측

전일 마감가:

$43.01

열려 있는:

$43.15

하루 거래량:

659.98K

시가총액:

$6.28B

수익:

$787.65M

순이익/손실:

$-366.29M

주가수익비율:

-15.01

EPS:

-2.87

순현금흐름:

$-335.52M

1주 성능:

+2.99%

1개월 성능:

+0.21%

6개월 성능:

-1.46%

1년 성능:

+21.31%

1일 변동 폭

$42.62

$43.62

52주 변동 폭

$34.32

$54.44

Ionis Pharmaceuticals Inc Stock (IONS) Company Profile

명칭

Ionis Pharmaceuticals Inc

부문

Healthcare (1190)

산업

Biotechnology (681)

전화

760-931-9200

주소

2855 Gazelle Court, Carlsbad, CA

직원

547

트위터

@ionispharma

다음 수익 날짜

2024-05-14

최신 SEC 제출 서류

IONS's Discussions on Twitter

Ionis Pharmaceuticals Inc Stock (IONS) Upgrades & Downgrades

날짜	액션	분석자	등급 변경
2024-01-02	업그레이드	BofA Securities	Neutral → Buy
2023-10-23	업그레이드	BofA Securities	Underperform → Neutral
2023-09-29	개시	Raymond James	Strong Buy
2023-07-31	업그레이드	Citigroup	Neutral → Buy
2023-06-07	재개	Piper Sandler	Overweight
2023-05-04	업그레이드	Citigroup	Sell → Neutral
2023-03-21	개시	Bernstein	Underperform
2022-12-21	다운그레이드	Morgan Stanley	Overweight → Equal-Weight
2022-09-09	재개	Morgan Stanley	Overweight
2022-07-18	재개	Oppenheimer	Outperform
2022-03-31	재개	Piper Sandler	Overweight
2022-03-01	개시	Citigroup	Sell
2022-03-01	개시	Guggenheim	Buy
2022-02-01	다운그레이드	BofA Securities	Buy → Underperform
2021-12-14	업그레이드	William Blair	Mkt Perform → Outperform
2021-05-07	업그레이드	UBS	Sell → Neutral
2021-03-01	업그레이드	Barclays	Underweight → Equal Weight
2020-12-16	개시	UBS	Sell
2020-12-15	업그레이드	Cowen	Market Perform → Outperform
2020-09-14	재개	JP Morgan	Neutral
2020-09-02	개시	The Benchmark Company	Hold
2020-06-01	재개	Oppenheimer	Outperform
2020-05-13	개시	RBC Capital Mkts	Outperform
2020-03-05	개시	Citigroup	Buy
2019-12-13	개시	Oppenheimer	Outperform
2019-11-13	개시	BofA/Merrill	Buy
2019-11-07	다운그레이드	Morgan Stanley	Equal-Weight → Underweight
2019-09-10	업그레이드	Bernstein	Mkt Perform → Outperform
2018-08-08	재확인	Stifel	Hold
2018-08-07	재확인	Stifel	Hold
2018-05-08	다운그레이드	Evercore ISI	Outperform → In-line
2017-10-06	재개	Goldman	Sell
2017-08-17	개시	Evercore ISI	Outperform
2017-08-09	재확인	Stifel	Hold
2017-03-10	다운그레이드	Goldman	Neutral → Sell
2016-12-28	재확인	BMO Capital Markets	Outperform
2016-12-27	재확인	Leerink Partners	Mkt Perform

모두보기

Ionis Pharmaceuticals Inc 주식(IONS)의 최신 뉴스

4D Molecular Therapeutics, Inc. (FDMT) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

Zacks Investment Research

Ionis Pharmaceuticals (IONS) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

Zacks Investment Research

The Latest Analyst Ratings For Ionis Pharmaceuticals

Benzinga

Can Ionis' (IONS) Wholly-Owned Drugs Cut Dependency on Collabs?

Zacks Investment Research

Ionis Pharmaceuticals (IONS) Down 2.8% Since Last Earnings Report: Can It Rebound?

Zacks Investment Research

Ionis (IONS) Drug Meets Mid-Stage MASH Study Goals

Zacks Investment Research

Ionis Pharmaceuticals Inc (IONS) 재무 분석

Ionis Pharmaceuticals Inc (IONS) 매출 2024

IONS은 2023-12-31 종료 분기에 대해 매출(지난 12개월)이 787.65M 달러로 보고했으며, 전년대비 +34.10% 상승했습니다.

Ionis Pharmaceuticals Inc (IONS) 순이익 2024

IONS은 2023-12-31 종료 분기에 대해 순이익(지난 12개월)이 -366.29M 달러로 보고했으며, 전년대비 -35.80% 감소했습니다.

Ionis Pharmaceuticals Inc (IONS) 현금흐름 2024

2023-12-31 종료 분기에 IONS은 현금흐름(지난 12개월)으로 -335.52M 달러를 기록했으며, 전년 대비 -13.94% 감소했습니다.

Ionis Pharmaceuticals Inc (IONS) 주당 순이익 2024

IONS이 보고한 2023-12-31 종료 분기의 주당 순이익(지난 12개월)은 -2.56달러이며, 전년 대비 -34.74% 감소했습니다.

Ionis Pharmaceuticals Inc 주식 (IONS) 내부자 거래

내부자 거래	관계	날짜	거래	비용	#주식	가치 ($)	#주식 총계
Baroldi Joseph	EVP, Chief Business Officer	Apr 16 '24	Sale	41.60	4,006	166,641	19,631
Birchler Brian	EVP, Corp and Development Ops	Apr 16 '24	Sale	41.66	905	37,698	46,156
Baroldi Joseph	EVP, Chief Business Officer	Apr 15 '24	Option Exercise	0.00	10,838	0	23,637
Birchler Brian	EVP, Corp and Development Ops	Apr 15 '24	Option Exercise	0.00	1,875	0	47,061
Monia Brett P	Chief Executive Officer	Feb 16 '24	Sale	44.49	387	17,219	173,751
Monia Brett P	Chief Executive Officer	Feb 02 '24	Sale	49.37	23,501	1,160,303	174,138
Cadoret-Manier Onaiza	EVP, Chf GL Pdt Str & Oper Ofc	Feb 02 '24	Sale	49.60	2,125	105,404	35,825
HOUGEN ELIZABETH L	EVP, Finance & CFO	Feb 02 '24	Sale	49.54	2,125	105,272	92,905
Schneider Eugene	EVP, Chf Clinical Develop Ofcr	Feb 02 '24	Sale	49.59	2,071	102,701	49,812
Geary Richard S	EVP, Chief Development Officer	Feb 02 '24	Sale	50.04	1,961	98,135	87,334